LCTX
Lineage Cell Therapeutics Inc
0.9303$
+2.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | -2,797.5% | – | – | |
| – | -24.7% | -24.9% | -30.7% | -0.7% | -8.3% | -32.0% | -57.2% | -16.7% | -4.8% | -12.0% | +14.8% | |
| – | +148.0% | -28.0% | -50.5% | +37.4% | -33.7% | -37.8% | +58.0% | +21.8% | +8.2% | +9.4% | -6.4% | |
| – | – | – | – | – | – | – | – | +41.2% | – | – | – | |
| – | – | -122.4% | – | -74.3% | -406.6% | – | +1,437.5% | -11.6% | -157.9% | – | – | |
| – | +1,004.1% | -52.6% | -47.5% | +147.9% | -86.6% | -85.5% | +453.1% | +16.7% | +63.2% | -16.2% | -7.6% | |
| – | +638.3% | +46.3% | -6.1% | – | +43.5% | -23.1% | -25.3% | -573.7% | – | -105.0% | +483.1% | |
| – | – | – | – | +7,479.1% | -99.9% | +62,767.5% | -71.2% | – | – | – | – | |
| – | -21.6% | -33.7% | -102.7% | -72.9% | -54.4% | -75.5% | +100.0% | -68.5% | +117.6% | -37.8% | -30.4% | |
| – | -45.8% | +532.2% | -89.3% | -302.9% | -79.9% | – | -100.1% | +60.0% | +68.8% | +0.0% | +9.3% | |
| – | +1.8% | -49.4% | +69.0% | -89.6% | -89.3% | +4,740.4% | +23.7% | -95.6% | +293.6% | +458.3% | -24.8% | |
| – | -46.9% | -258.1% | – | -190.1% | – | – | +0.0% | -292.0% | – | -56.9% | -148.5% | |
| – | – | – | – | – | – | – | – | – | -4,626.3% | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.